

Kenneth N Olivier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9700158/publications.pdf>

Version: 2024-02-01

65
papers

9,960
citations

87888

38
h-index

110387

64
g-index

65
all docs

65
docs citations

65
times ranked

9122
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e178-e190.	9.1	51
2	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0221221.	3.2	13
3	CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018. <i>ERJ Open Research</i> , 2022, 8, 00724-2021.	2.6	18
4	HALT-ing Nontuberculous Mycobacteria in CF Centers. Is There Something in The Water?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	5.6	1
5	Impact of periprocedural subcutaneous parathyroid hormone on control of hypocalcaemia in APS-1/APECED patients undergoing invasive procedures. <i>Clinical Endocrinology</i> , 2021, 94, 377-383.	2.4	3
6	Fatal autoimmune pneumonitis requiring bilobectomy and omental flap repair in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101476.	0.4	1
7	Genome-wide association study in patients with pulmonary <i>Mycobacterium avium</i> complex disease. <i>European Respiratory Journal</i> , 2021, 58, 1902269.	6.7	16
8	Pulmonary Manifestations of GATA2 Deficiency. <i>Chest</i> , 2021, 160, 1350-1359.	0.8	21
9	Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design. <i>PLoS ONE</i> , 2021, 16, e0261628.	2.5	10
10	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
11	Antimicrobial peptides against drug resistant <i>Mycobacterium abscessus</i> . <i>Research in Microbiology</i> , 2020, 171, 211-214.	2.1	7
12	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
13	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
14	Antibacterial activity of high-dose nitric oxide against pulmonary <i>Mycobacterium abscessus</i> disease. <i>Access Microbiology</i> , 2020, 2, acmi000154.	0.5	18
15	Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 390-403.	0.7	3
16	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	52
17	Amikacin exposure and susceptibility of macrolide-resistant <i>Mycobacterium abscessus</i> . <i>ERJ Open Research</i> , 2019, 5, 00154-2018.	2.6	6
18	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 947-951.	5.6	53

#	ARTICLE	IF	CITATIONS
19	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
20	Survival of pathogenic <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> in <i>Acanthamoeba castellanii</i> . <i>Research in Microbiology</i> , 2018, 169, 56-60.	2.1	7
21	ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1473-1475.	5.6	6
22	Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010–2014. <i>Annals of the American Thoracic Society</i> , 2018, 15, 817-826.	3.2	113
23	<i>Pneumocystis</i> Colonization in Asthmatic Patients not Receiving Oral Corticosteroid Therapy. <i>Journal of Investigative Medicine</i> , 2017, 65, 800-802.	1.6	5
24	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
25	Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, <i>TTK</i> , for Pulmonary Nontuberculous Mycobacterial Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1599-1604.	5.6	28
26	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 814-823.	5.6	212
27	Adult Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 982-992.	0.8	282
28	MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections. <i>JCI Insight</i> , 2017, 2, .	5.0	30
29	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. <i>JCI Insight</i> , 2016, 1, .	5.0	219
30	Mediastinal and Disseminated <i>Mycobacterium kansasii</i> Disease in GATA2 Deficiency. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2169-2173.	3.2	11
31	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
32	Bronchiectasis and connective tissue diseases. <i>Current Pulmonology Reports</i> , 2016, 5, 169-176.	1.3	1
33	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. <i>Thorax</i> , 2016, 71, 88-90.	5.6	274
34	Pulmonary Manifestations of the Autoimmune Lymphoproliferative Syndrome. A Retrospective Study of a Unique Patient Cohort. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1279-1288.	3.2	13
35	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i> , 2016, 71, i1-i22.	5.6	348
36	Lady Windermere Dissected: More Form Than Fastidious. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1674-1676.	3.2	8

#	ARTICLE	IF	CITATIONS
37	A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma. BMC Infectious Diseases, 2015, 16, 54.	2.9	18
38	Beyond Marfan: the clinical impact of bronchiectasis and non-tuberculous mycobacteria in connective tissue diseases. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1409-1409.	1.2	5
39	Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 618-628.	5.6	136
40	Clonal Diversification and Changes in Lipid Traits and Colony Morphology in Mycobacterium abscessus Clinical Isolates. Journal of Clinical Microbiology, 2015, 53, 3438-3447.	3.9	48
41	Semiquantitative Culture Analysis during Therapy for <i>Mycobacterium avium</i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 754-760.	5.6	67
42	The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Medicine, 2015, 21, 1223-1227.	30.7	387
43	Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI). , 2015, , .		1
44	High-level Relatedness among <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> Strains from Widely Separated Outbreaks. Emerging Infectious Diseases, 2014, 20, 364-371.	4.3	108
45	Environmental Risks for Nontuberculous Mycobacteria. Individual Exposures and Climatic Factors in the Cystic Fibrosis Population. Annals of the American Thoracic Society, 2014, 11, 1032-1038.	3.2	67
46	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110 β result in T cell senescence and human immunodeficiency. Nature Immunology, 2014, 15, 88-97.	14.5	575
47	Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. Annals of the American Thoracic Society, 2014, 11, 30-35.	3.2	156
48	GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood, 2014, 123, 809-821.	1.4	599
49	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> . Science, 2014, 345, 1623-1627.	12.6	745
50	Epidemiology of Nontuberculous Mycobacterial Infections and Associated Chronic Macrolide Use among Persons with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 807-812.	5.6	123
51	Abnormal Nasal Nitric Oxide Production, Ciliary Beat Frequency, and Toll-like Receptor Response in Pulmonary Nontuberculous Mycobacterial Disease Epithelium. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1374-1381.	5.6	70
52	Adaptability and Persistence of the Emerging Pathogen Bordetella petrii. PLoS ONE, 2013, 8, e65102.	2.5	17
53	Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare Beneficiaries. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 881-886.	5.6	547
54	Respiratory Outbreak of <i>Mycobacterium abscessus</i> Subspecies <i>massiliense</i> in a Lung Transplant and Cystic Fibrosis Center. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 231-232.	5.6	277

#	ARTICLE	IF	CITATIONS
55	Lung Manifestations in an Autopsy-Based Series of Pulmonary or Disseminated Nontuberculous Mycobacterial Disease. <i>Chest</i> , 2012, 141, 1203-1209.	0.8	43
56	Adult-Onset Immunodeficiency in Thailand and Taiwan. <i>New England Journal of Medicine</i> , 2012, 367, 725-734.	27.0	431
57	Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. <i>Blood</i> , 2011, 118, 3715-3720.	1.4	131
58	Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. <i>Blood</i> , 2010, 115, 1519-1529.	1.4	299
59	Familial Clustering of Pulmonary Nontuberculous Mycobacterial Disease. <i>Chest</i> , 2010, 137, 629-634.	0.8	74
60	Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 970-976.	5.6	487
61	Cohort Study of Molecular Identification and Typing of <i>Mycobacterium abscessus</i> , <i>Mycobacterium massiliense</i> , and <i>Mycobacterium bolletii</i> . <i>Journal of Clinical Microbiology</i> , 2009, 47, 1985-1995.	3.9	210
62	Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 617-618.	2.9	31
63	Pulmonary Nontuberculous Mycobacterial Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1066-1074.	5.6	356
64	Nontuberculous Mycobacteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 828-834.	5.6	595
65	Nontuberculous Mycobacteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 835-840.	5.6	214